Sage Therapeutics, Inc.
SAGEHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | $41.2M | $86.5M | $7.7M | $6.3M | $1.11B | $6.9M |
| Operating income | −$432.4M | −$579.8M | −$547.0M | −$460.9M | $596.2M | −$708.1M |
| Net income | −$400.7M | −$541.5M | −$532.8M | −$457.9M | $606.1M | −$680.2M |
| Total assets | $547.2M | $882.3M | $1.36B | $1.83B | $2.16B | $1.08B |
| Total liabilities | $82.1M | $82.7M | $103.8M | $96.3M | $86.9M | $139.5M |
| Equity | $465.1M | $799.5M | $1.25B | $1.73B | $2.07B | $944.7M |
| EPS (diluted) | $-6.59 | $-9.05 | $-8.98 | $-7.80 | $11.43 | $-13.38 |
| Shares out. | 60.1M | 59.7M | 59.1M | 58.4M | 51.9M | 47.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- −1048.3%
- Net margin
- −971.5%
- Return on equity
- −86.1%
- Return on assets
- −73.2%
- Return on capital (ROCE)
- −90.9%
- Liabilities / assets
- 15.0%
- Debt / equity
- 0.18×
- Book value / share
- $7.74
- Revenue growth (YoY)
- −52.3%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -11.55distress
- Accruals / assets
- −24.4%clean
- Piotroski F-Score
- 1/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Jul 31, 2025 | 509,127 | 1.0 | -77.0% |
| Jul 15, 2025 | 2.2M | 1.2 | -21.1% |
| Jun 30, 2025 | 2.8M | 1.0 | -46.6% |
| Jun 13, 2025 | 5.3M | 8.2 | +0.9% |
| May 30, 2025 | 5.2M | 7.3 | +3.8% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsJul 31, 2025
- Results of operationsJul 30, 2025
- Entered a material agreement · Regulation FD disclosureJun 16, 2025
- Director / officer change · Shareholder voteJun 13, 2025
- Results of operationsApr 29, 2025
- Director / officer change · Other material eventMar 4, 2025
- Results of operationsFeb 11, 2025
- Other material eventJan 27, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.